Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-low or HER2-ultralow”

6 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 6 of 6 results

Testing effectiveness (Phase 2)Looking for participantsNCT07198724
What this trial is testing

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

Who this might be right for
Metastatic Breast CancerHER2 Low Breast CarcinomaHER2-negative Breast Cancer+2 more
Kristina A. Fanucci 65
Not applicableLooking for participantsNCT05573893
What this trial is testing

PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan

Who this might be right for
Breast NeoplasmsBreast CancerNeoplasm Metastasis
AstraZeneca 800
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07757230
What this trial is testing

A Phase II Study of SSGJ-612 Plus a HER2-Targeted ADC in HR-Positive, HER2-Low or HER2-Ultralow Expression Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Shenyang Sunshine Pharmaceutical Co., LTD. 87
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07701941
What this trial is testing

Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

Who this might be right for
Hormone Receptor PositiveHER2-low or HER2-ultralowUnresectable or Metastatic Breast Cancer
Daiichi Sankyo 220
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07619365
What this trial is testing

Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer

Who this might be right for
Breast CancerAdvanced Breast CancerMetastatic Breast Cancer
Washington University School of Medicine 60
Large-scale testing (Phase 3)Looking for participantsNCT07543536
What this trial is testing

Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer

Who this might be right for
Advanced/Metastatic Breast CancerHER2+, Low, or Ultralow Advanced/Metastatic Breast Cancer
Sun Yat-sen University 132